Reuters logo
8 个月内
BRIEF-Blueprint Medicines announces Proof-of-Concept Data from Global Phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma
2016年11月28日 / 晚上11点27分 / 8 个月内

BRIEF-Blueprint Medicines announces Proof-of-Concept Data from Global Phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma

1 分钟阅读

Nov 28 (Reuters) - Blueprint Medicines Corp

* Blueprint Medicines announces proof-of-concept data from global phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma

* Blueprint Medicines Corp says radiographic tumor reduction observed in 5 of 10 patients with FGFR4 pathway activation Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below